25 XP   0   0   10

Protagenic Therapeutics
Buy, Hold or Sell?

Let's analyse Protagenic together

PenkeI guess you are interested in Protagenic Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Protagenic Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Protagenic Therapeutics

I send you an email if I find something interesting about Protagenic Therapeutics.

Quick analysis of Protagenic (30 sec.)










What can you expect buying and holding a share of Protagenic? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.83
Expected worth in 1 year
$0.21
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.62
Return On Investment
-39.5%

For what price can you sell your share?

Current Price per Share
$1.57
Expected price per share
$1.1535 - $1.9
How sure are you?
50%

1. Valuation of Protagenic (5 min.)




Live pricePrice per Share (EOD)

$1.57

Intrinsic Value Per Share

$-11.68 - $-7.13

Total Value Per Share

$-10.86 - $-6.30

2. Growth of Protagenic (5 min.)




Is Protagenic growing?

Current yearPrevious yearGrowGrow %
How rich?$3.6m$7.2m-$3m-71.4%

How much money is Protagenic making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m-$721.8k-$767.8k-51.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Protagenic (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#779 / 1010

Most Revenue
#743 / 1010

Most Profit
#272 / 1010

Most Efficient
#178 / 1010

What can you expect buying and holding a share of Protagenic? (5 min.)

Welcome investor! Protagenic's management wants to use your money to grow the business. In return you get a share of Protagenic.

What can you expect buying and holding a share of Protagenic?

First you should know what it really means to hold a share of Protagenic. And how you can make/lose money.

Speculation

The Price per Share of Protagenic is $1.5687. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Protagenic.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Protagenic, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.83. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Protagenic.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-24.1%-0.34-21.4%-0.17-10.5%-0.20-12.6%-0.14-9.1%
Usd Book Value Change Per Share0.000.0%-0.15-9.9%-0.20-12.7%0.052.9%0.053.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.15-9.9%-0.20-12.7%0.052.9%0.053.3%
Usd Price Per Share1.75-1.65-0.86-1.51-0.85-
Price to Earnings Ratio-1.16--1.28--1.31--2.67--1.64-
Price-to-Total Gains Ratio4,692,213.64-1,173,047.28--5.97-246,971.76-167,586.24-
Price to Book Ratio2.12-1.74-0.55--3.17--1.02-
Price-to-Total Gains Ratio4,692,213.64-1,173,047.28--5.97-246,971.76-167,586.24-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.5687
Number of shares637
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.150.05
Usd Total Gains Per Share-0.150.05
Gains per Quarter (637 shares)-98.6128.94
Gains per Year (637 shares)-394.43115.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-394-4040116106
20-789-7980232222
30-1183-11920347338
40-1578-15860463454
50-1972-19800579570
60-2367-23740695686
70-2761-27680810802
80-3155-31620926918
90-3550-3556010421034
100-3944-3950011581150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%14.084.01.014.1%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.029.02.022.5%22.061.016.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%2.00.097.02.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.029.02.022.5%22.061.016.022.2%

Fundamentals of Protagenic

About Protagenic Therapeutics

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-12 15:55:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Protagenic Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Protagenic earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Protagenic Therapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y9.3%-9.3%
5Y9.3%10Y4.6%+4.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y9.3%-436.8%+446.1%
10Y4.6%-597.3%+601.9%
1.1.2. Return on Assets

Shows how efficient Protagenic is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • -38.8% Return on Assets means that Protagenic generated $-0.39 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Protagenic Therapeutics:

  • The MRQ is -38.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.8%TTM-30.2%-8.6%
TTM-30.2%YOY-8.8%-21.4%
TTM-30.2%5Y-66.0%+35.8%
5Y-66.0%10Y-74.9%+9.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.8%-13.3%-25.5%
TTM-30.2%-12.8%-17.4%
YOY-8.8%-11.6%+2.8%
5Y-66.0%-13.8%-52.2%
10Y-74.9%-15.6%-59.3%
1.1.3. Return on Equity

Shows how efficient Protagenic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • -45.7% Return on Equity means Protagenic generated $-0.46 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Protagenic Therapeutics:

  • The MRQ is -45.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -36.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.7%TTM-36.8%-8.9%
TTM-36.8%YOY-10.1%-26.8%
TTM-36.8%5Y-11.4%-25.4%
5Y-11.4%10Y-19.5%+8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.7%-16.9%-28.8%
TTM-36.8%-16.1%-20.7%
YOY-10.1%-14.9%+4.8%
5Y-11.4%-19.3%+7.9%
10Y-19.5%-20.1%+0.6%

1.2. Operating Efficiency of Protagenic Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Protagenic is operating .

  • Measures how much profit Protagenic makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Protagenic Therapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y9.0%-9.0%
5Y9.0%10Y4.5%+4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y9.0%-486.2%+495.2%
10Y4.5%-628.4%+632.9%
1.2.2. Operating Ratio

Measures how efficient Protagenic is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Protagenic Therapeutics:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.140+0.140
5Y-0.14010Y-0.070-0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y-0.1405.679-5.819
10Y-0.0707.823-7.893

1.3. Liquidity of Protagenic Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Protagenic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.41 means the company has $6.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Protagenic Therapeutics:

  • The MRQ is 6.410. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.404. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.410TTM5.404+1.006
TTM5.404YOY11.919-6.516
TTM5.4045Y6.996-1.593
5Y6.99610Y4.735+2.261
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4103.863+2.547
TTM5.4044.169+1.235
YOY11.9195.337+6.582
5Y6.9966.122+0.874
10Y4.7356.434-1.699
1.3.2. Quick Ratio

Measures if Protagenic is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • A Quick Ratio of 10.41 means the company can pay off $10.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Protagenic Therapeutics:

  • The MRQ is 10.415. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.660. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.415TTM7.660+2.755
TTM7.660YOY23.228-15.568
TTM7.6605Y10.817-3.157
5Y10.81710Y6.525+4.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4153.504+6.911
TTM7.6603.991+3.669
YOY23.2285.371+17.857
5Y10.8176.088+4.729
10Y6.5256.395+0.130

1.4. Solvency of Protagenic Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Protagenic assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Protagenic to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Protagenic assets are financed with 15.2% credit (debt) and the remaining percentage (100% - 15.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Protagenic Therapeutics:

  • The MRQ is 0.152. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.189. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.152TTM0.189-0.038
TTM0.189YOY0.123+0.066
TTM0.1895Y1.329-1.140
5Y1.32910Y2.355-1.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1520.339-0.187
TTM0.1890.337-0.148
YOY0.1230.271-0.148
5Y1.3290.368+0.961
10Y2.3550.388+1.967
1.4.2. Debt to Equity Ratio

Measures if Protagenic is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Protagenic to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.9% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Protagenic Therapeutics:

  • The MRQ is 0.179. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.236. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.179TTM0.236-0.057
TTM0.236YOY0.142+0.094
TTM0.2365Y0.099+0.137
5Y0.09910Y0.196-0.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1790.392-0.213
TTM0.2360.403-0.167
YOY0.1420.335-0.193
5Y0.0990.427-0.328
10Y0.1960.461-0.265

2. Market Valuation of Protagenic Therapeutics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Protagenic generates.

  • Above 15 is considered overpriced but always compare Protagenic to the Biotechnology industry mean.
  • A PE ratio of -1.16 means the investor is paying $-1.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Protagenic Therapeutics:

  • The EOD is -1.038. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.158. Based on the earnings, the company is expensive. -2
  • The TTM is -1.284. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.038MRQ-1.158+0.120
MRQ-1.158TTM-1.284+0.126
TTM-1.284YOY-1.313+0.030
TTM-1.2845Y-2.666+1.382
5Y-2.66610Y-1.645-1.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.038-2.300+1.262
MRQ-1.158-2.656+1.498
TTM-1.284-2.718+1.434
YOY-1.313-4.145+2.832
5Y-2.666-6.258+3.592
10Y-1.645-6.315+4.670
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Protagenic Therapeutics:

  • The EOD is -1.405. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.567. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.697. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.405MRQ-1.567+0.162
MRQ-1.567TTM-1.697+0.131
TTM-1.697YOY-2.429+0.732
TTM-1.6975Y-6.179+4.482
5Y-6.17910Y-3.567-2.612
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.405-2.974+1.569
MRQ-1.567-3.306+1.739
TTM-1.697-3.508+1.811
YOY-2.429-5.613+3.184
5Y-6.179-8.378+2.199
10Y-3.567-8.873+5.306
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Protagenic is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.12 means the investor is paying $2.12 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Protagenic Therapeutics:

  • The EOD is 1.897. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.116. Based on the equity, the company is underpriced. +1
  • The TTM is 1.735. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.897MRQ2.116-0.219
MRQ2.116TTM1.735+0.381
TTM1.735YOY0.546+1.189
TTM1.7355Y-3.172+4.908
5Y-3.17210Y-1.016-2.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8971.914-0.017
MRQ2.1162.1160.000
TTM1.7352.097-0.362
YOY0.5462.881-2.335
5Y-3.1723.550-6.722
10Y-1.0163.936-4.952
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Protagenic Therapeutics.

3.1. Institutions holding Protagenic Therapeutics

Institutions are holding 7.963% of the shares of Protagenic Therapeutics.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc0.74780331662150.6525
2023-12-31Geode Capital Management, LLC0.568202519900
2023-12-31FNY Investment Advisers, LLC0.42280.01891875000
2023-12-31State Street Corporation0.311401381200
2023-12-31Susquehanna International Group, LLP0.2976013197131970
2023-12-31Tower Research Capital LLC0.20350.00019026337559.7239
2023-12-31Wells Fargo & Co0.000602614
2023-12-31Morgan Stanley - Brokerage Accounts00100
2023-12-31Bank of America Corp00100
2023-09-30Advisor Group Holdings, Inc.000-2764-100
Total 2.55190.019113178+14024+12.4%

3.2. Funds holding Protagenic Therapeutics

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.721403199600
2024-02-29Fidelity Extended Market Index0.37940.00011682700
2024-02-29Fidelity Nasdaq Composite Index0.11290500700
2024-02-29Fidelity Series Total Market Index0.07420328900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07090.0001314400
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05690.0001252550.1984
2023-12-31Northern Trust Extended Eq Market Idx0.05590247800
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05590247800
2024-03-31State St US Extended Mkt Indx NL Cl C0.02760.0001122500
2023-12-31SSgA U.S. Extended Market Index Class I0.02760122500
2024-02-29Vanguard U.S. Eq Idx £ Acc0.02640117000
2023-12-31SSgA U.S. Total Market Index Strategy0.0080353-8-2.2161
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00230.000110200
2024-02-29Fidelity U.S. Equity Index Ins Trust0.0011051510
2024-02-29Spartan Extended Market Index Pool E0.000602500
Total 1.62110.000571895+48+0.1%

3.3. Insider Transactions

Insiders are holding 53.509% of the shares of Protagenic Therapeutics.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-12Alexander K ArrowBUY80000.81

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Protagenic Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.000-0.155+41505530%-0.199+53316140%0.045-100%0.053-100%
Book Value Per Share--0.8270.953-13%1.633-49%0.823+1%0.498+66%
Current Ratio--6.4105.404+19%11.919-46%6.996-8%4.735+35%
Debt To Asset Ratio--0.1520.189-20%0.123+23%1.329-89%2.355-94%
Debt To Equity Ratio--0.1790.236-24%0.142+26%0.099+81%0.196-9%
Dividend Per Share----0%-0%-0%-0%
Eps---0.378-0.336-11%-0.165-56%-0.197-48%-0.143-62%
Free Cash Flow Per Share---0.279-0.266-5%-0.109-61%-0.123-56%-0.083-70%
Free Cash Flow To Equity Per Share---0.279-0.266-5%-0.109-61%0.023-1328%0.058-581%
Gross Profit Margin--1.0161.004+1%1.000+2%1.001+2%1.036-2%
Intrinsic Value_10Y_max---7.126--------
Intrinsic Value_10Y_min---11.685--------
Intrinsic Value_1Y_max---0.388--------
Intrinsic Value_1Y_min---0.762--------
Intrinsic Value_3Y_max---1.414--------
Intrinsic Value_3Y_min---2.658--------
Intrinsic Value_5Y_max---2.740--------
Intrinsic Value_5Y_min---4.942--------
Market Cap6957388.431-12%7761477.5007329052.820+6%3797580.063+104%7995810.307-3%4757517.621+63%
Net Profit Margin----0%-0%0.093-100%0.046-100%
Operating Margin----0%-0%0.090-100%0.045-100%
Operating Ratio----0%-0%-0.1400%-0.0700%
Pb Ratio1.897-12%2.1161.735+22%0.546+287%-3.172+250%-1.016+148%
Pe Ratio-1.038+10%-1.158-1.284+11%-1.313+13%-2.666+130%-1.645+42%
Price Per Share1.569-12%1.7501.653+6%0.856+104%1.511+16%0.854+105%
Price To Free Cash Flow Ratio-1.405+10%-1.567-1.697+8%-2.429+55%-6.179+294%-3.567+128%
Price To Total Gains Ratio4206100.305-12%4692213.6381173047.276+300%-5.966+100%246971.756+1800%167586.242+2700%
Quick Ratio--10.4157.660+36%23.228-55%10.817-4%6.525+60%
Return On Assets---0.388-0.302-22%-0.088-77%-0.660+70%-0.749+93%
Return On Equity---0.457-0.368-19%-0.101-78%-0.114-75%-0.195-57%
Total Gains Per Share--0.000-0.155+41505530%-0.199+53316140%0.045-100%0.053-100%
Usd Book Value--3668117.0004225625.250-13%7243002.250-49%4000804.200-8%2429596.775+51%
Usd Book Value Change Per Share--0.000-0.155+41505530%-0.199+53316140%0.045-100%0.053-100%
Usd Book Value Per Share--0.8270.953-13%1.633-49%0.823+1%0.498+66%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.378-0.336-11%-0.165-56%-0.197-48%-0.143-62%
Usd Free Cash Flow---1238403.000-1180030.000-5%-484222.000-61%-564323.950-54%-387721.225-69%
Usd Free Cash Flow Per Share---0.279-0.266-5%-0.109-61%-0.123-56%-0.083-70%
Usd Free Cash Flow To Equity Per Share---0.279-0.266-5%-0.109-61%0.023-1328%0.058-581%
Usd Market Cap6957388.431-12%7761477.5007329052.820+6%3797580.063+104%7995810.307-3%4757517.621+63%
Usd Price Per Share1.569-12%1.7501.653+6%0.856+104%1.511+16%0.854+105%
Usd Profit---1676184.000-1489646.250-11%-721806.500-57%-914889.550-45%-676142.950-60%
Usd Revenue----0%-0%-24025.5000%-12012.7500%
Usd Total Gains Per Share--0.000-0.155+41505530%-0.199+53316140%0.045-100%0.053-100%
 EOD+2 -6MRQTTM+13 -17YOY+9 -215Y+7 -2510Y+12 -20

4.2. Fundamental Score

Let's check the fundamental score of Protagenic Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.038
Price to Book Ratio (EOD)Between0-11.897
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.415
Current Ratio (MRQ)Greater than16.410
Debt to Asset Ratio (MRQ)Less than10.152
Debt to Equity Ratio (MRQ)Less than10.179
Return on Equity (MRQ)Greater than0.15-0.457
Return on Assets (MRQ)Greater than0.05-0.388
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Protagenic Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.414
Ma 20Greater thanMa 501.533
Ma 50Greater thanMa 1001.301
Ma 100Greater thanMa 2001.093
OpenGreater thanClose1.470
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,323
Total Liabilities655
Total Stockholder Equity3,668
 As reported
Total Liabilities 655
Total Stockholder Equity+ 3,668
Total Assets = 4,323

Assets

Total Assets4,323
Total Current Assets4,200
Long-term Assets123
Total Current Assets
Cash And Cash Equivalents 1,288
Short-term Investments 2,768
Other Current Assets 144
Total Current Assets  (as reported)4,200
Total Current Assets  (calculated)4,200
+/-0
Long-term Assets
Property Plant Equipment 123
Long-term Assets Other 0
Long-term Assets  (as reported)123
Long-term Assets  (calculated)123
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities655
Long-term Liabilities0
Total Stockholder Equity3,668
Total Current Liabilities
Other Current Liabilities 655
Total Current Liabilities  (as reported)655
Total Current Liabilities  (calculated)655
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -30,778
Accumulated Other Comprehensive Income -114
Other Stockholders Equity 34,559
Total Stockholder Equity (as reported)3,668
Total Stockholder Equity (calculated)3,668
+/-0
Other
Cash and Short Term Investments 4,056
Common Stock Shares Outstanding 4,378
Liabilities and Stockholders Equity 4,323
Net Debt -1,288
Net Working Capital 3,545



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302004-06-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-30
> Total Assets 
0
0
0
12,600
14,400
15,700
16,600
15,769
15,769
20,800
20,700
21,476
21,476
24,100
22,900
22,931
22,931
22,992
22,238
22,390
22,390
22,920
23,513
23,272
23,272
23,724
22,187
21,529
21,529
17,751
18,344
13,700
7,000
0
4
9
11
4
4
5,500
24,089
23,593
24,790
23,963
201,867
203,069
205,170
78,763
76,649
70,305
70,086
44,598
39,852
32,765
26,648
19,342
19,342
15,025
14,074
0
0
0
246
246
261
148
133
60
26
3,752
3,752
3,587
3,162
3,162
2,455
2,220
1,781
1,781
1,092
990
697
465
350
287
842
842
1,188
1,002
879
196
12,062
11,657
11,060
11,060
9,015
8,254
8,037
7,666
6,919
5,433
4,323
4,323
4,3234,3235,4336,9197,6668,0378,2549,01511,06011,06011,65712,0621968791,0021,1888428422873504656979901,0921,7811,7812,2202,4553,1623,1623,5873,7523,752266013314826124624600014,07415,02519,34219,34226,64832,76539,85244,59870,08670,30576,64978,763205,170203,069201,86723,96324,79023,59324,0895,50044119407,00013,70018,34417,75121,52921,52922,18723,72423,27223,27223,51322,92022,39022,39022,23822,99222,93122,93122,90024,10021,47621,47620,70020,80015,76915,76916,60015,70014,40012,600000
   > Total Current Assets 
0
0
0
6,400
7,600
9,300
10,200
9,023
9,023
12,900
13,000
12,968
12,968
15,400
13,400
14,356
14,356
14,889
13,847
13,736
13,736
14,435
14,486
13,769
13,769
14,337
12,788
12,054
12,054
10,640
11,780
8,600
7,000
0
4
9
11
4
4
5,000
22,588
21,378
22,211
21,117
52,803
43,368
51,988
47,797
45,737
39,462
34,786
31,914
27,538
20,730
15,297
12,315
12,315
8,579
9,063
0
0
0
245
245
260
146
132
59
25
3,751
3,751
3,586
3,161
3,161
2,454
2,219
1,780
1,780
1,092
990
696
464
349
287
842
842
1,188
1,002
879
196
12,062
11,657
11,060
11,060
9,015
8,254
8,036
7,665
6,918
5,377
4,200
4,200
4,2004,2005,3776,9187,6658,0368,2549,01511,06011,06011,65712,0621968791,0021,1888428422873494646969901,0921,7801,7802,2192,4543,1613,1613,5863,7513,75125591321462602452450009,0638,57912,31512,31515,29720,73027,53831,91434,78639,46245,73747,79751,98843,36852,80321,11722,21121,37822,5885,00044119407,0008,60011,78010,64012,05412,05412,78814,33713,76913,76914,48614,43513,73613,73613,84714,88914,35614,35613,40015,40012,96812,96813,00012,9009,0239,02310,2009,3007,6006,400000
       Cash And Cash Equivalents 
0
0
0
100
100
1,800
1,800
323
323
0
100
34
34
400
300
133
133
28
20
0
25
55
18
16
16
16
29
11
11
31
24
100
4,500
0
0
4
4
2
2
500
17,720
13,989
12,991
7,612
16,932
17,152
21,888
20,410
22,646
20,435
17,591
16,913
12,475
7,268
4,249
6,319
6,319
2,309
1,998
0
0
0
101
101
150
57
62
10
4
3,751
3,751
3,489
3,100
3,100
628
952
400
400
236
432
362
419
340
277
799
799
1,181
989
671
192
11,933
460
541
541
339
158
215
138
219
153
1,288
1,288
1,2881,28815321913821515833954154146011,9331926719891,1817997992773404193624322364004009526283,1003,1003,4893,7513,75141062571501011010001,9982,3096,3196,3194,2497,26812,47516,91317,59120,43522,64620,41021,88817,15216,9327,61212,99113,98917,7205002244004,500100243111112916161618552502028133133300400343410003233231,8001,800100100000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,838
13,047
0
3,950
4,245
243
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,826
1,152
1,286
1,286
850
494
250
0
250
0
0
0
0
0
0
0
0
10,395
9,830
9,830
8,530
7,994
7,764
7,512
5,823
5,119
2,768
2,768
2,7682,7685,1195,8237,5127,7647,9948,5309,8309,83010,3950000000025002504948501,2861,2861,1521,82600000000000000000000000002434,2453,950013,0472,8380000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
2,400
3,200
2,800
3,500
2,824
2,824
4,000
5,300
4,945
4,945
6,000
5,700
6,104
6,104
6,603
5,568
6,160
6,160
6,058
6,450
5,802
5,802
5,693
4,619
4,241
4,241
2,646
3,865
2,900
2,200
0
4
4
6
0
4
3,500
3,627
4,839
6,268
9,111
18,856
22,269
20,321
19,456
18,001
14,330
14,168
12,358
13,151
12,504
10,170
5,431
5,431
4,477
5,378
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000005,3784,4775,4315,43110,17012,50413,15112,35814,16814,33018,00119,45620,32122,26918,8569,1116,2684,8393,6273,5004064402,2002,9003,8652,6464,2414,2414,6195,6935,8025,8026,4506,0586,1606,1605,5686,6036,1046,1045,7006,0004,9454,9455,3004,0002,8242,8243,5002,8003,2002,400000
       Other Current Assets 
0
0
0
400
200
500
400
941
359
1,500
1,200
1,280
857
1,600
200
0
699
1,015
919
0
725
1,079
1,027
0
691
1,025
954
0
730
989
924
200
0
0
0
0
0
0
3
0
1,241
2,550
2,952
1,556
3,968
3,947
3,149
3,686
4,847
4,697
3,027
2,643
1,912
958
878
0
565
787
787
0
0
0
0
144
110
89
70
49
21
0
0
97
61
60
0
115
95
95
6
64
83
45
10
10
0
43
6
13
208
4
129
802
0
689
146
102
57
14
875
104
0
144
144010487514571021466890802129420813643010104583646959511506061970021497089110144000078778756508789581,9122,6433,0274,6974,8473,6863,1493,9473,9681,5562,9522,5501,2410300000020092498973009541,02569101,0271,07972509191,01569902001,6008571,2801,2001,500359941400500200400000
   > Long-term Assets 
0
0
0
6,200
6,800
6,400
6,400
6,746
6,746
7,900
7,700
8,508
8,508
8,700
9,500
8,575
8,575
8,103
8,391
8,654
8,654
8,485
9,027
9,503
9,503
9,387
9,399
9,475
9,475
7,111
6,564
5,100
0
0
0
0
0
0
0
500
1,501
2,215
2,579
2,846
149,064
159,701
153,182
30,966
30,912
30,843
35,300
12,684
12,314
12,035
11,351
7,027
7,027
6,446
5,011
0
0
0
1
1
1
2
1
1
1
2
2
1
0
1
1
1
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
56
123
123
1231235622200000000000000111110111012211121110005,0116,4467,0277,02711,35112,03512,31412,68435,30030,84330,91230,966153,182159,701149,0642,8462,5792,2151,50150000000005,1006,5647,1119,4759,4759,3999,3879,5039,5039,0278,4858,6548,6548,3918,1038,5758,5759,5008,7008,5088,5087,7007,9006,7466,7466,4006,4006,8006,200000
       Property Plant Equipment 
0
0
0
2,900
3,100
3,100
3,200
256
256
300
4,500
236
236
4,400
4,500
237
237
230
247
236
236
227
222
257
257
248
222
228
228
176
150
3,100
0
0
0
0
0
0
0
100
865
859
836
860
3,104
3,815
4,286
3,525
3,500
3,320
3,646
3,553
3,466
3,309
3,172
2,692
2,692
2,406
2,484
0
0
0
1
1
1
2
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
56
123
123
1231235622200000000000000111111111112111121110002,4842,4062,6922,6923,1723,3093,4663,5533,6463,3203,5003,5254,2863,8153,10486083685986510000000003,1001501762282282222482572572222272362362472302372374,5004,4002362364,5003002562563,2003,1003,1002,900000
       Goodwill 
0
0
0
3,200
3,200
0
0
3,055
3,055
0
0
3,336
3,336
0
0
3,126
3,126
3,020
2,966
2,912
2,912
2,805
2,752
2,698
2,698
2,597
2,547
2,491
2,491
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
97,980
101,373
100,852
11,075
11,981
12,096
12,096
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
404
0
0
0
404
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000404000404000000000000000000000012,09612,09611,98111,075100,852101,37397,9800000000000000002,4912,4912,5472,5972,6982,6982,7522,8052,9122,9122,9663,0203,1263,126003,3363,336003,0553,055003,2003,200000
       Intangible Assets 
0
0
0
0
0
3,200
3,100
0
3,000
3,000
2,900
0
3,300
3,200
3,200
0
3,100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
460
1,208
904
599
41,298
45,903
44,044
12,508
11,117
10,426
12,850
7,253
7,080
6,907
6,733
3,083
3,083
2,887
1,380
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000001,3802,8873,0833,0836,7336,9077,0807,25312,85010,42611,11712,50844,04445,90341,2985999041,208460000000000000000000000003,10003,2003,2003,30002,9003,0003,00003,1003,20000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
5,500
7,400
2,100
3,100
2,470
2,470
7,200
6,800
7,529
7,529
9,800
8,800
9,658
9,658
10,048
9,082
8,948
8,948
9,061
9,633
9,706
9,706
10,221
8,865
8,655
8,655
8,319
9,150
8,800
4,200
100
100
163
173
176
176
4,300
4,937
4,583
7,171
7,098
36,562
37,018
40,636
24,114
23,954
19,050
20,345
19,251
17,564
14,697
11,975
11,170
11,170
16,139
19,725
0
0
0
316
316
589
602
704
767
892
736
736
648
685
685
578
537
562
562
533
667
908
827
729
651
1,477
1,477
1,934
2,023
2,029
2,179
1,264
1,287
1,118
1,118
756
872
1,120
1,252
1,505
1,280
655
655
6556551,2801,5051,2521,1208727561,1181,1181,2871,2642,1792,0292,0231,9341,4771,47765172982790866753356256253757868568564873673689276770460258931631600019,72516,13911,17011,17011,97514,69717,56419,25120,34519,05023,95424,11440,63637,01836,5627,0987,1714,5834,9374,3001761761731631001004,2008,8009,1508,3198,6558,6558,86510,2219,7069,7069,6339,0618,9488,9489,08210,0489,6589,6588,8009,8007,5297,5296,8007,2002,4702,4703,1002,1007,4005,500000
   > Total Current Liabilities 
0
0
0
5,000
5,700
2,000
3,100
2,470
2,470
7,200
6,900
7,529
7,529
9,800
8,800
9,658
9,658
9,384
8,518
8,584
8,584
8,797
9,633
9,706
9,706
10,221
8,865
8,655
8,655
8,319
9,150
8,800
400
100
100
163
173
176
176
4,300
4,848
4,516
7,127
7,076
22,750
17,805
25,718
24,114
23,954
19,050
20,345
16,566
14,941
12,070
9,334
10,263
10,263
15,233
18,822
0
0
0
141
141
589
602
189
767
892
736
736
648
685
685
578
537
562
562
533
667
908
827
729
651
1,197
1,197
800
712
655
651
603
724
800
800
463
553
1,120
1,252
1,505
1,280
655
655
6556551,2801,5051,2521,1205534638008007246036516557128001,1971,19765172982790866753356256253757868568564873673689276718960258914114100018,82215,23310,26310,2639,33412,07014,94116,56620,34519,05023,95424,11425,71817,80522,7507,0767,1274,5164,8484,3001761761731631001004008,8009,1508,3198,6558,6558,86510,2219,7069,7069,6338,7978,5848,5848,5189,3849,6589,6588,8009,8007,5297,5296,9007,2002,4702,4703,1002,0005,7005,000000
       Short-term Debt 
0
0
0
0
0
0
0
0
300
3,400
4,400
3,875
3,875
4,800
5,700
5,458
5,458
5,585
4,998
4,083
4,083
5,156
6,144
4,929
4,929
5,660
4,986
4,325
4,325
4,161
5,183
4,000
0
0
95
138
163
163
163
0
669
89
89
99
588
0
1,794
1,858
1,881
0
0
0
0
0
0
0
0
3,202
4,020
0
0
0
0
265
415
415
0
565
665
73
73
0
517
517
504
435
426
420
0
0
0
0
0
0
0
0
0
0
0
0
0
441
0
186
0
0
344
369
394
420
0
0
00420394369344001860441000000000000042042643550451751707373665565041541526500004,0203,202000000001,8811,8581,7940588998989669016316316313895004,0005,1834,1614,3254,3254,9865,6604,9294,9296,1445,1564,0834,0834,9985,5855,4585,4585,7004,8003,8753,8754,4003,40030000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
517
517
504
435
426
420
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
344
369
394
420
0
0
00420394369344000000000000000000420426435504517517000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
1,800
2,900
0
2,300
3,600
2,400
0
3,400
4,800
3,100
0
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
20
2
0
2
0
2,370
2,147
5,417
3,257
10,764
4,322
7,993
7,194
10,598
7,008
6,956
6,257
5,074
4,522
4,264
0
4,470
2,787
5,231
0
0
0
0
138
164
172
168
174
192
0
52
21
168
76
74
102
11
0
118
41
52
36
48
36
163
36
43
24
142
234
185
274
279
279
334
139
670
175
158
244
0
0
00244158175670139334279279274185234142244336163364836524111801110274761682152019217416817216413800005,2312,7874,47004,2644,5225,0746,2576,9567,00810,5987,1947,9934,32210,7643,2575,4172,1472,37002022050000000000000000003,00003,1004,8003,40002,4003,6002,30002,9001,80000000
       Other Current Liabilities 
0
0
0
5,000
5,700
200
200
2,470
2,470
200
100
3,654
3,654
200
0
0
4,200
3,799
3,520
0
4,501
3,641
3,489
0
4,777
4,561
3,879
0
4,330
4,158
3,967
4,800
400
100
100
4
8
0
11
0
1,809
2,280
1,621
3,269
3,628
13,483
1,866
14,910
9,862
9,895
10,683
9,584
9,015
7,548
5,070
0
5,519
8,627
9,029
0
0
0
0
3
10
15
21
28
35
662
489
627
685
685
578
537
562
562
414
626
855
790
681
615
332
1,161
757
688
513
417
418
451
0
521
129
414
106
883
914
661
0
655
655066191488310641412952104514184175136887571,1613326156817908556264145625625375786856856274896623528211510300009,0298,6275,51905,0707,5489,0159,58410,6839,8959,86214,9101,86613,4833,6283,2691,6212,2801,8090110841001004004,8003,9674,1584,33003,8794,5614,77703,4893,6414,50103,5203,7994,200002003,6543,6541002002,4702,4702002005,7005,000000
   > Long-term Liabilities 
0
0
0
500
1,700
100
2,900
0
2,600
7,000
6,800
0
3,875
9,600
8,800
0
5,458
664
564
364
364
264
6,144
0
4,929
5,660
4,986
0
4,325
4,161
5,183
4,000
3,800
0
144
158
166
0
166
0
89
67
44
22
13,812
19,213
14,918
9,204
14,092
9,155
9,662
2,685
2,623
2,627
2,641
907
907
906
903
0
0
0
175
175
579
587
515
739
857
0
125
21
0
0
0
0
0
0
118
41
52
36
48
36
279
279
1,134
1,311
1,374
1,528
661
562
318
318
293
319
1,014
565
0
0
0
0
00005651,0143192933183185626611,5281,3741,3111,13427927936483652411180000002112508577395155875791751750009039069079072,6412,6272,6232,6859,6629,15514,0929,20414,91819,21313,812224467890166016615814403,8004,0005,1834,1614,32504,9865,6604,92906,1442643643645646645,45808,8009,6003,87506,8007,0002,60002,9001001,700500000
> Total Stockholder Equity
0
0
0
7,000
7,000
13,600
13,500
13,299
13,299
13,600
13,900
13,947
13,947
14,300
14,100
0
13,273
12,944
13,156
0
13,442
13,859
13,880
0
13,566
13,503
13,322
0
12,874
9,432
9,194
5,000
2,700
-100
-100
-154
-163
0
-172
0
18,997
18,875
17,328
16,582
165,051
165,844
164,343
54,389
52,695
51,255
49,741
25,347
22,288
18,068
14,673
0
8,172
-1,114
-5,651
0
0
0
0
-21
-266
-385
-497
-628
-786
3,016
3,016
2,939
2,477
2,477
1,877
1,683
1,219
1,219
560
323
-211
-362
-379
-364
-634
-634
-746
-1,021
-1,150
-1,983
10,798
10,371
9,942
9,942
8,258
7,382
6,918
6,414
5,414
4,153
3,668
3,668
3,6683,6684,1535,4146,4146,9187,3828,2589,9429,94210,37110,798-1,983-1,150-1,021-746-634-634-364-379-362-2113235601,2191,2191,6831,8772,4772,4772,9393,0163,016-786-628-497-385-266-210000-5,651-1,1148,172014,67318,06822,28825,34749,74151,25552,69554,389164,343165,844165,05116,58217,32818,87518,9970-1720-163-154-100-1002,7005,0009,1949,43212,874013,32213,50313,566013,88013,85913,442013,15612,94413,273014,10014,30013,94713,94713,90013,60013,29913,29913,50013,6007,0007,000000
   Common Stock
0
0
0
0
0
0
0
35
35
0
0
35
35
0
0
0
35
35
35
0
35
35
35
0
35
35
35
0
35
35
35
0
0
300
300
287
287
0
287
0
118
120
121
120
225
228
230
230
230
231
236
236
236
236
236
0
70
70
70
0
0
0
0
0
0
0
1,000
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
0
0
0
0
0
0
000000222222111111111111111111100001,00000000007070700236236236236236231230230230228225120121120118028702872873003000035353503535350353535035353500035350035350000000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-300
-300
0
-200
-200
-200
0
-300
-300
-300
0
-600
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-34
-34
-34
-38
-190
0
-2,581
-286
-312
-183
-89
-20
26
1
17
-1,813
42
80
32
0
0
0
0
0
0
0
-1,000
0
0
0
-148
-174
0
-182
-174
-167
0
-168
-165
-165
-171
-173
-173
-173
0
-172
-174
-173
-172
-171
-171
-172
0
-248
-450
-615
-677
-629
-586
-618
0
-114
-1140-618-586-629-677-615-450-2480-172-171-171-172-173-174-1720-173-173-173-171-165-165-1680-167-174-1820-174-148000-1,0000000000328042-1,81317126-20-89-183-312-286-2,5810-190-38-34-34-3400000000000000000000000-6000-300-300-3000-200-200-2000-300-30000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,200
10,400
18,000
17,900
17,556
17,556
17,800
17,800
17,556
17,556
17,900
17,900
0
17,556
16,589
16,589
0
16,589
16,569
16,569
0
16,569
16,614
16,605
0
16,605
16,605
16,605
16,700
16,600
-300
-300
-287
-287
0
-287
0
18,185
18,948
19,349
19,583
168,366
167,901
168,984
173,294
172,813
173,192
173,963
173,450
173,780
174,076
174,301
0
176,106
176,449
176,481
0
0
0
0
1,053
1,053
1,053
1,053
1,053
1,053
0
10,210
11,138
-182
11,240
11,741
11,994
-168
12,228
12,836
13,097
13,358
13,809
14,070
14,209
-172
14,687
15,643
16,326
16,720
17,093
31,420
31,873
-248
32,410
32,957
33,171
33,371
33,538
33,705
33,872
0
34,559
34,559033,87233,70533,53833,37133,17132,95732,410-24831,87331,42017,09316,72016,32615,64314,687-17214,20914,07013,80913,35813,09712,83612,228-16811,99411,74111,240-18211,13810,21001,0531,0531,0531,0531,0531,0530000176,481176,449176,1060174,301174,076173,780173,450173,963173,192172,813173,294168,984167,901168,36619,58319,34918,94818,1850-2870-287-287-300-30016,60016,70016,60516,60516,605016,60516,61416,569016,56916,56916,589016,58916,58917,556017,90017,90017,55617,55617,80017,80017,55617,55617,90018,00010,40010,200000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-28
Gross Profit-28-28
 
Operating Income (+$)
Gross Profit-28
Operating Expense-4,499
Operating Income-4,527-4,527
 
Operating Expense (+$)
Research Development3,320
Selling General Administrative1,207
Selling And Marketing Expenses28
Operating Expense4,4994,555
 
Net Interest Income (+$)
Interest Income303
Interest Expense-108
Other Finance Cost-19
Net Interest Income176
 
Pretax Income (+$)
Operating Income-4,527
Net Interest Income176
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,000-4,053
EBIT - interestExpense = -4,635
-5,000
-4,893
Interest Expense108
Earnings Before Interest and Taxes (EBIT)-4,527-4,893
Earnings Before Interest and Taxes (EBITDA)-4,499
 
After tax Income (+$)
Income Before Tax-5,000
Tax Provision-0
Net Income From Continuing Ops-3,926-5,000
Net Income-5,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,527
Total Other Income/Expenses Net-474-176
 

Technical Analysis of Protagenic
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Protagenic. The general trend of Protagenic is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Protagenic's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Protagenic Therapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.79 < 1.87 < 1.9.

The bearish price targets are: 1.24 > 1.2 > 1.1535.

Tweet this
Protagenic Therapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Protagenic Therapeutics. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Protagenic Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Protagenic Therapeutics. The current macd is 0.03404052.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protagenic price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Protagenic. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Protagenic price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Protagenic Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartProtagenic Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Protagenic Therapeutics. The current adx is 25.69.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Protagenic shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Protagenic Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Protagenic Therapeutics. The current sar is 1.1791014.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Protagenic Therapeutics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Protagenic Therapeutics. The current rsi is 56.41. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Protagenic Therapeutics Daily Relative Strength Index (RSI) ChartProtagenic Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Protagenic Therapeutics. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protagenic price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Protagenic Therapeutics Daily Stochastic Oscillator ChartProtagenic Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Protagenic Therapeutics. The current cci is -22.57986462.

Protagenic Therapeutics Daily Commodity Channel Index (CCI) ChartProtagenic Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Protagenic Therapeutics. The current cmo is 14.08.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Protagenic Therapeutics Daily Chande Momentum Oscillator (CMO) ChartProtagenic Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Protagenic Therapeutics. The current willr is -35.77726218.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Protagenic is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Protagenic Therapeutics Daily Williams %R ChartProtagenic Therapeutics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Protagenic Therapeutics.

Protagenic Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Protagenic Therapeutics. The current atr is 0.21421711.

Protagenic Therapeutics Daily Average True Range (ATR) ChartProtagenic Therapeutics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Protagenic Therapeutics. The current obv is 59,755.

Protagenic Therapeutics Daily On-Balance Volume (OBV) ChartProtagenic Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Protagenic Therapeutics. The current mfi is 60.41.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Protagenic Therapeutics Daily Money Flow Index (MFI) ChartProtagenic Therapeutics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Protagenic Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Protagenic Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Protagenic Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.414
Ma 20Greater thanMa 501.533
Ma 50Greater thanMa 1001.301
Ma 100Greater thanMa 2001.093
OpenGreater thanClose1.470
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Protagenic with someone you think should read this too:
  • Are you bullish or bearish on Protagenic? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Protagenic? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Protagenic Therapeutics

I send you an email if I find something interesting about Protagenic Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Protagenic Therapeutics.

Receive notifications about Protagenic Therapeutics in your mailbox!